Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Hematol. 2010 Sep;17(5):450-6. doi: 10.1097/MOH.0b013e32833c0760.

The role of thromboprophylaxis in cancer patients: emerging data.

Author information

  • 1James P. Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York 14642, USA.

Abstract

PURPOSE OF REVIEW:

Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in cancer patients. A significant proportion of cancer-associated VTE occurs in the ambulatory setting and is associated with poorer outcomes and reduced survival. Risk for VTE is influenced by patient, cancer and treatment-specific factors.

RECENT FINDINGS:

Recent studies have identified biomarkers associated with increased VTE risk in malignancy, including leukocyte and platelet counts, tissue factor, prothrombin split products, D-dimer, P-selectin, factor VIII and C-reactive protein. Recent and ongoing clinical trials have focused on VTE prophylaxis with low-molecular weight heparins in high-risk cancer outpatients, particularly those with pancreatic cancer. These studies have yielded encouraging preliminary results but whether thromboprophylaxis provides significant benefit to unselected cancer outpatients remains unclear.

SUMMARY:

A risk stratification model incorporating known risk factors and biomarkers can identify those patients at highest risk. This review focuses on emerging data regarding risk assessment and benefit of thromboprophylaxis in patients with cancer.

PMID:
20601873
[PubMed - indexed for MEDLINE]
PMCID:
PMC3088308
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk